S
Salomon M. Stemmer
Researcher at Rabin Medical Center
Publications - 215
Citations - 12740
Salomon M. Stemmer is an academic researcher from Rabin Medical Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 43, co-authored 189 publications receiving 9651 citations. Previous affiliations of Salomon M. Stemmer include University of New South Wales & Tel Aviv University.
Papers
More filters
Journal ArticleDOI
The oncologist's role in managing depression, anxiety, and demoralization with advanced cancer.
TL;DR: Depression and anxiety constitute most psychological distress and will be described in formal psychiatric terms (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) and subjective descriptions and management modalities for depression, anxiety, and demoralization are discussed.
Journal ArticleDOI
Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
Noa Hasky,Shiri Uri-Belapolsky,Keren Goldberg,Irit Miller,Hadas Grossman,Salomon M. Stemmer,Irit Ben-Aharon,Ruth Shalgi +7 more
TL;DR: This study demonstrates that different chemotherapy agents affect the ovary via diverse mechanisms and thus the administration of GnRH-a concomitantly, could be beneficial to a subpopulation of patients treated with cyclophosphamide-based protocols.
Journal ArticleDOI
Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment.
Journal ArticleDOI
Pasireotide for malignant insulinoma
Amit Tirosh,Amit Tirosh,Salomon M. Stemmer,Salomon M. Stemmer,Evgeny Solomonov,Eldad Elnekave,Wolfgang Saeger,Yelena Ravkin,Kobi Nir,Yeela Talmor,Ilan Shimon,Ilan Shimon +11 more
TL;DR: Pasireotide monthly injections achieved improved glycemic control in a patient with malignant insulinoma and recurrent hypoglycemic events compared with other medical treatments.
Journal ArticleDOI
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study.
E. Van Cutsem,C.-P. Li,Elżbieta Nowara,G. Aprile,Malcolm A.S. Moore,I Federowicz,J-L. van Laethem,C.-H. Hsu,C K Tham,Salomon M. Stemmer,R Lipp,A Zeaiter,A Fittipaldo,Z Csutor,Barbara Klughammer,X Meng,Tudor-Eliade Ciuleanu +16 more
TL;DR: The erlotinib dose-escalation strategy induced rash in some patients; there was no evidence that the higher dose translated into increased benefit.